- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
Related Questions
What is the expected timeline for data readout from the expanded study?
How does the expanded trial enrollment compare to competitors' programs in platinumāresistant ovarian cancer?
Will the trial expansion increase the likelihood of FDA approval or fastātrack designation?
What is the potential market size and revenue upside if SB221 succeeds?
Could the expansion attract strategic partnership or licensing opportunities?
What are the risks associated with the expanded patient population in terms of safety and efficacy?
How might the trial expansion impact Sonnet's share dilution or financing needs?
What is the anticipated impact on Sonnet's stock price in the short term?
How does the expansion align with Sonnet's overall pipeline and strategic priorities?
How will the expansion of the SB221 trial affect Sonnet's cash runway?